

## BrainCool AB (publ): New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S.

BrainCool AB reports that the American Medical Association (AMA) have announced the approval of a new Current Procedural Terminology (CPT®) code for reduction of complications associated with oral mucositis in patients undergoing chemotherapy, thereby creating a clear path for reimbursement of the Cooral® System.

The new CPT code, an action resulted from the AMA CPT Editorial Panel's September 21st - 23rd 2023 meeting, will become effective for use in 2024, and establishing a pathway for widespread adoption and reimbursement. Worth highlighting is that the code application was included by the CPT Committee as a 'consent' application. Meaning the application was approved without further discussions and a vote.

### **CEO Martin Waleij comments**

- " This is a major milestone for Cooral® System, and most of all for patients suffering from oral mucositis as a result from cancer treatment. It further recognizes BrainCool's innovative technology of Cooral® System, with the creation of a new unique procedure category".

### **Contacts**

#### **For more information**

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

### **About Us**

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

### **Attachments**

[BrainCool AB \(publ\): New CPT Code from AMA for Cooral® System supports Pathway to Reimbursement in the U.S.](#)